Pituitary-thyroid axis in critical illness. 1987

J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen

Severe nonthyroidal illness has been claimed to cause secondary hypothyroidism. We reevaluated this concept measuring serum free T4 and free T3 by an ultrafiltration method and serum TSH by an ultrasensitive technique (detection limit, and serum TSH by an ultrasensitive technique (detection limit, 0.05 mU/L). Forty-five critically ill patients suffering from hepatic coma (n = 10), terminal cancer (n = 9), stroke (n = 8), and respiratory insufficiency not treated (n = 7) and treated (n = 11) with dopamine were studied. The mortality rate was 80%. No patients received glucocorticoids, and only patients in the last group received dopamine. Serum total as well as free thyroid hormone index values were grossly reduced in the majority of the patients. The 34 patients not receiving dopamine in general had normal values of serum free T4 (32 of 34) and free T3 (31 of 34), measurable TSH (33 of 34), and detectable TSH responses to iv TRH (33 of 34). In contrast, the dopamine-treated patients had reduced serum free T4 and TSH levels compared to normal subjects (P less than 0.05), as well as reduced TSH responses to TRH (P less than 0.01). Serum free T4 and free T3 were below the normal range in 3 patients and 1 patient, respectively, and serum TSH was below the detection limit in 2 patients. We conclude that critically ill patients with nonthyroidal illness not receiving dopamine have normal pituitary-thyroid function, whereas dopamine induces some degree of secondary hypothyroidism.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010901 Pituitary Function Tests Examinations that evaluate functions of the pituitary gland. Pituitary Gland Function Tests,Function Test, Pituitary,Function Tests, Pituitary,Pituitary Function Test,Test, Pituitary Function,Tests, Pituitary Function
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
December 2001, Best practice & research. Clinical endocrinology & metabolism,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
November 2009, The Netherlands journal of medicine,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
December 2006, Endocrinology and metabolism clinics of North America,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
January 2006, AACN clinical issues,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
December 2007, Reviews in endocrine & metabolic disorders,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
October 2011, Best practice & research. Clinical endocrinology & metabolism,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
January 2006, Critical care clinics,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
January 2011, Expert review of endocrinology & metabolism,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
September 2008, Bone,
J Faber, and C Kirkegaard, and B Rasmussen, and H Westh, and M Busch-Sørensen, and I W Jensen
January 2009, Critical care (London, England),
Copied contents to your clipboard!